Pharmaceuticals

Bevacizumab Biosimilars Market Expected to Hit $2.42 Billion by 2030 at 8.2% CAGR

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Bevacizumab Biosimilars Market During The Forecast Period 2026–2030?

The bevacizumab biosimilars market size has experienced substantial expansion in recent times. This market is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, the market’s growth was driven by factors such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the rising demand for cost-effective biologics, government incentives for biosimilars, and progress in recombinant DNA technology.

The bevacizumab biosimilars market is projected for substantial expansion in the coming years, reaching a valuation of $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is fueled by several factors, including a rise in biosimilar approvals, the widening presence in emerging markets, the incorporation of AI into drug development processes, a rising demand for outpatient oncology services, and strategic partnerships among pharmaceutical firms. Key trends anticipated during this period encompass a greater acceptance of biosimilars in cancer treatment, the availability of more economical treatment options, an increase in regulatory clearances for biosimilars, the broadening of hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer treatment facilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Underlying Factors Are Accelerating The Growth Of The Bevacizumab Biosimilars Market?

An increasing number of cancer cases is anticipated to stimulate expansion within the bevacizumab biosimilar market in the future. Cancer incidence denotes the count of new cancer diagnoses within a specific demographic over a defined duration. Bevacizumab, a biologic, works by hindering tumor angiogenesis, leading to reduced tumor size and inhibited growth, and it demonstrates comparable effectiveness and safety to its reference biologics for individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2025, the NHS England, a UK-based government department, reported 354,820 new cancer diagnoses in England in 2023, representing an increase of 8,605 compared to 2022. Consequently, the growing incidence of cancer cases fuels the bevacizumab biosimilars market.

What Market Segments Are Evaluated Within The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

What Industry Trends Are Redefining The Bevacizumab Biosimilars Market?

Key companies operating within the bevacizumab biosimilars market are concentrating on technological advancements, such as next-generation formulations with broadened indications, to satisfy the increasing demand for more adaptable and economical biologic treatments across both oncology and non-oncology conditions. These advanced formulations modify the core bevacizumab antibody for new delivery methods or uses, enabling non-cancerous applications (like in ophthalmology) or more patient-friendly dosing, while retaining the same VEGF-neutralizing mechanism as traditional intravenous bevacizumab. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab), designed for oncology uses, makes the treatment costs for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more attainable for a greater number of patients. Versavo is supplied in 100 mg and 400 mg single-use vials, matching standard bevacizumab dosing, and offers a biosimilar cost-benefit that helps alleviate the financial burden on healthcare systems and patients who rely on anti-VEGF therapy.

Who Are The Top Market Participants Influencing The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Read the full bevacizumab biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Projected To Dominate The Bevacizumab Biosimilars Market During The Forecast Period?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Bevacizumab Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795